Ariella Oppenheim

Title: Ariella Oppenheim: Innovator in Viral Capsid Proteins

Introduction

Ariella Oppenheim is a prominent inventor based in Jerusalem, Israel. She has made significant contributions to the field of viral capsid proteins, focusing on their potential as medicaments for treating various pathologic disorders. With a total of 5 patents, her work is paving the way for innovative therapeutic solutions.

Latest Patents

Oppenheim's latest patents revolve around viral capsid proteins and their applications in treating pathologic disorders. Specifically, her inventions relate to the viral capsid proteins VP1, VP2, and VP3, with a preference for SV40 VP1. These proteins, along with any peptides, fragments, mutants, derivatives, and mixtures thereof, serve as active ingredients in compositions aimed at addressing disorders linked to the inactivation of cellular proteins involved in quality control processes, particularly chaperones. Furthermore, her inventions provide methods for treating such disorders and outline the use of SV40 capsid proteins in the preparation of pharmaceutical compositions.

Career Highlights

Throughout her career, Ariella Oppenheim has worked with notable organizations, including Gene Vector Technologies and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Her experience in these companies has allowed her to advance her research and contribute to the scientific community.

Collaborations

Oppenheim has collaborated with esteemed colleagues, including Ziv Sandalon and Nava Dalyot. These partnerships have enriched her research endeavors and fostered innovation in her field.

Conclusion

Ariella Oppenheim's work in viral capsid proteins exemplifies her dedication to advancing medical science. Her innovative patents and collaborations highlight her significant impact on the treatment of pathologic disorders.